[SARS-CoV-2 neutralizing monoclonal antibodies and nanobodies: a review].

Chen, Yulei; Lin, Jinjin; Zheng, Peiyi; Cao, Minjie; Jin, Tengchuan

Chen, Yulei; Lin, Jinjin; Zheng, Peiyi; Cao, Minjie; Jin, Tengchuan.

Afiliación

Chen Y; College of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, Fujian, China.
Lin J; College of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, Fujian, China.
Zheng P; School of Basic Medical Sciences, University of Science and Technology of China, Hefei 230027, Anhui, China.
Cao M; College of Ocean Food and Biological Engineering, Jimei University, Xiamen 361021, Fujian, China.
Jin T; School of Basic Medical Sciences, University of Science and Technology of China, Hefei 230027, Anhui, China.

Sheng Wu Gong Cheng Xue Bao ; 38(9): 3173-3193, 2022 Sep 25.

Article en Zh | MEDLINE | ID: mdl-36151792

Asunto(s)

COVID-19; Anticuerpos de Dominio Único; Enzima Convertidora de Angiotensina 2; Anticuerpos Monoclonales; Anticuerpos Neutralizantes; Anticuerpos Antivirales; Humanos; Peptidil-Dipeptidasa A/química; Peptidil-Dipeptidasa A/metabolismo; Unión Proteica; SARS-CoV-2; Glicoproteína de la Espiga del Coronavirus/química; Glicoproteína de la Espiga del Coronavirus/metabolismo

Palabras clave

COVID-19; SARS-CoV-2; monoclonal antibody; nanobody; receptor binding domain

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos de Dominio Único / COVID-19 Límite: Humans Idioma: Zh Revista: Sheng Wu Gong Cheng Xue Bao Asunto de la revista: BIOTECNOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google